Catalyst Wire Dossier Catalyst Wire Dossier

Garadacimab

garadacimab · CSL Behring
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for Garadacimab, covering 2023-06-29 to 2026-06-02. Get the full timeline:

Most recent: Clinical Trial Results: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]

See pricing